Cohort Study: Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia – “Bacterial superinfection within 48 hours of intubation was detected in 21 percent of patients”.
Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia – American Journal of Respiratory and Critical Care Medicine Commentary: Potential Overuse of Antibiotics Found in Patients with Severe COVID-19 Pneumonia – American Thoracic Society Commentary on Twitter Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia ? Open Access? https://t.co/MaCZkKrQdQ pic.twitter.com/sscICvqYjS — […]
The post Cohort Study: Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia – “Bacterial superinfection within 48 hours of intubation was detected in 21 percent of patients”. appeared first on Links Medicus.
COVID: how worried should we be about the new AY.4.2 lineage of the coronavirus?
COVID: how worried should we be about the new AY.4.2 lineage of the coronavirus? – The Conversation
The post COVID: how worried should we be about the new AY.4.2 lineage of the coronavirus? appeared first on Links Medicus.
Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.
Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19 – New England Journal of Medicine
The post Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19. appeared first on Links Medicus.
Systematic Review: Antibiotics for the treatment of COVID‐19 – “We are certain that risk of death in hospitalized COVID‐19 patients is not reduced by treatment with azithromycin after 28 days”.
Antibiotics for the treatment of COVID‐19 – Cochrane Library Commentary on Twitter JUST PUBLISHED – Are #antibiotics an effective treatment for #COVID19 & do they cause unwanted effects? https://t.co/EVHduxmtdD New Cochrane Review looked at evidence from 11 studies: ❌ antibiotic azithromycin is not an effective treatment, ?not enough research on other types. — The […]
The post Systematic Review: Antibiotics for the treatment of COVID‐19 – “We are certain that risk of death in hospitalized COVID‐19 patients is not reduced by treatment with azithromycin after 28 days”. appeared first on Links Medicus.
RCT: The association of Varenicline and Nicotine patch was not better than Varenicline alone to increase smoking abstinence; there was also no difference between 24-week vs. 12-week treatment courses in abstinence rates.
Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial – JAMA (free for a limited period) Editorial: Is There a Role for Combined Use of Varenicline and Nicotine Patch or Extended Treatment Duration to Enhance Smoking Cessation? – JAMA (free for a limited period) Commentary: […]
The post RCT: The association of Varenicline and Nicotine patch was not better than Varenicline alone to increase smoking abstinence; there was also no difference between 24-week vs. 12-week treatment courses in abstinence rates. appeared first on Links Medicus.
Opinion | COVID STEROID-2: Double the steroid, double the fun? – “Dexamethasone 6 mg/day alone is likely suboptimal for most patients with severe COVID pneumonia. Dexamethasone 12 mg/day may provide a reasonable intensity of immunomodulation”.
COVID STEROID-2: Double the steroid, double the fun? – PulmCrit Original study: RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support. Commentary on Twitter COVID-STEROID 2?5% lower mortality with 12 mg […]
The post Opinion | COVID STEROID-2: Double the steroid, double the fun? – “Dexamethasone 6 mg/day alone is likely suboptimal for most patients with severe COVID pneumonia. Dexamethasone 12 mg/day may provide a reasonable intensity of immunomodulation”. appeared first on Links Medicus.
Review: Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? – The Lancet Respiratory Medicine Commentary on Twitter New on our #COVID19 resource centre—Personal View: Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Read in @LancetRespirMed: https://t.co/ZOTgVQYd6w pic.twitter.com/7BwRPLzsib — The Lancet (@TheLancet) October 23, 2021
The post Review: Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? appeared first on Links Medicus.
Perspective | The flawed science of antibody testing for SARS-CoV-2 immunity.
The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity – JAMA
The post Perspective | The flawed science of antibody testing for SARS-CoV-2 immunity. appeared first on Links Medicus.
RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support.
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial – JAMA Editorial: Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic – JAMA Commentary on Twitter In a randomized trial […]
The post RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support. appeared first on Links Medicus.
[Press release – not published yet] A phase 3 trial with more than 10,000 participants showed a booster dose of the Pfizer/BioNTech vaccine had an efficacy of 95.6% against disease; there were 5 cases in the booster group and 109 cases in the non-boosted
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine Commentary: Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say – CNN Commentaries on Twitter This will presumably mean everyone gets boosters early next year. That’s great, because they do […]
The post [Press release – not published yet] A phase 3 trial with more than 10,000 participants showed a booster dose of the Pfizer/BioNTech vaccine had an efficacy of 95.6% against disease; there were 5 cases in the booster group and 109 cases in the non-boosted group, not classified according to severity. appeared first on Links Medicus.